TAVR-Fueled Growth and 2026 Guidance Might Change The Case For Investing In Edwards Lifesciences (EW)

• In February 2026, Edwards Lifesciences reported fourth-quarter 2025 sales of US$1,569.6 million alongside a sharp drop in quarterly net income, while issuing first-quarter 2026 sales guidance of US$1.55 billion to US$1.63 billion and full-year 2026 sales growth guidance of 8% to 10% with EPS of US$2.90 to US$3.05.
• A key highlight was the robust year-over-year growth in transcatheter aortic valve replacement (TAVR) sales, which now account for roughly three-quarters of Edwards’ revenue and underpin management’s confidence in its 2026 outlook.
• Now we’ll examine how strong TAVR sales momentum and reaffirmed 2026 guidance may influence Edwards Lifesciences’ broader investment narrative.

AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Edwards Lifesciences Investment Narrative Recap

To own Edwards Lifesciences, you need to believe its leadership in transcatheter heart therapies, especially TAVR, can translate solid procedure growth into consistent earnings despite cost and pricing pressures. The latest results show strong TAVR-driven sales but a sharp drop in net income, so the key near term catalyst is whether management can convert this top line momentum into margin stability. The biggest current risk remains execution on costs and tariffs rather than this specific quarter, which does not appear to change that materially.

The reaffirmed 2026 guidance for 8% to 10% sales growth and EPS of US$2.90 to US$3.05 stands out against the weak recent earnings comparison. It directly ties the current TAVR performance to management’s confidence in meeting near term financial targets, while also implicitly testing their ability to manage tariff headwinds and higher operating expenses. How well Edwards tracks against this guidance will likely frame investor reactions to any future product or regulatory milestones.

Yet against this constructive guidance, investors should still be aware that rising tariffs and operating costs could...

Read the full narrative on Edwards Lifesciences (it's free!)

Edwards Lifesciences' narrative projects $7.6 billion revenue and $1.8 billion earnings by 2028. This requires 10.0% yearly revenue growth and roughly a $0.4 billion earnings increase from $1.4 billion today.

Uncover how Edwards Lifesciences' forecasts yield a $97.11 fair value, a 23% upside to its current price.

Exploring Other Perspectives

Three members of the Simply Wall St Community value Edwards Lifesciences between US$70.82 and US$97.11, highlighting how far opinions can diverge. When you set these views against management’s 2026 sales and EPS guidance, it becomes even more important to compare different expectations for how effectively Edwards can turn strong TAVR revenue into sustainable earnings.

Explore 3 other fair value estimates on Edwards Lifesciences - why the stock might be worth as much as 23% more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Edwards Lifesciences research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Edwards Lifesciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Edwards Lifesciences' overall financial health at a glance.

Curious About Other Options?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.
• Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com